Literature DB >> 20073508

pH-responsive polymeric sirna carriers sensitize multidrug resistant ovarian cancer cells to doxorubicin via knockdown of polo-like kinase 1.

Danielle S W Benoit1, Scott M Henry, Andrew D Shubin, Allan S Hoffman, Patrick S Stayton.   

Abstract

Small interfering RNA (siRNA)-based therapies have great potential for the treatment of debilitating diseases such as cancer, but an effective delivery strategy for siRNA is elusive. Here, pH-responsive complexes were developed for the delivery of siRNA in order to sensitize drug-resistant ovarian cancer cells (NCI/ADR-RES) to doxorubicin. The electrostatic complexes consisted of a cationic micelle used as a nucleating core, siRNA, and a pH-responsive endosomolytic polymer. Cationic micelles were formed from diblock copolymers of dimethylaminoethyl methacrylate (pDMAEMA) and butyl methacrylate (pDbB). The hydrophobic butyl core mediated micelle formation while the positively charged pDMAEMA corona enabled siRNA condensation. To enhance cytosolic delivery through endosomal release, a pH-responsive copolymer of poly(styrene-alt-maleic anhydride) (pSMA) was electrostatically complexed with the positively charged siRNA/micelle to form a ternary complex. Complexes exhibited size (30-105 nm) and charge (slightly positive) properties important for endocytosis and were found to be noncytotoxic and mediate uptake in >70% of ovarian cancer cells after 1 h of incubation. The pH-responsive ternary complexes were used to deliver siRNA against polo-like kinase 1 (plk1), a gene upregulated in many cancers and responsible for cell cycle progression, to ovarian cancer cell lines. Treatment resulted in approximately 50% reduction of plk1 gene expression in the drug-resistant NCI/ADR-RES ovarian cancer cell model and in the drug-sensitive parental cell line, OVCAR8. This knockdown functionally sensitized NCI/ADR-RES cells to doxorubicin at levels similar to OVCAR8. Sensitization occurred through a p53 signaling pathway, as indicated by caspase 3/7 upregulation following plk1 knockdown and doxorubicin treatment, and this effect could be abrogated using a p53 inhibitor. To demonstrate the potential for dual delivery from this polymer system, micelle cores were subsequently loaded with doxorubicin and utilized in ternary complexes to achieve cell sensitization through simultaneous siRNA and drug delivery from a single carrier. These results show knockdown of plk1 results in sensitization of multidrug resistant cells to doxorubicin, and this combination of gene silencing and small molecule drug delivery may prove useful to achieve potent therapeutic effects.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20073508      PMCID: PMC2920053          DOI: 10.1021/mp9002255

Source DB:  PubMed          Journal:  Mol Pharm        ISSN: 1543-8384            Impact factor:   4.939


  74 in total

1.  Polo-like kinase 1 regulates mitotic arrest after UV irradiation through dephosphorylation of p53 and inducing p53 degradation.

Authors:  Jie Chen; Gu Dai; Yi-Qian Wang; Sheng Wang; Fei-Yan Pan; Bin Xue; Dong-Hong Zhao; Chao-Jun Li
Journal:  FEBS Lett       Date:  2006-05-30       Impact factor: 4.124

Review 2.  Strategies for silencing human disease using RNA interference.

Authors:  Daniel H Kim; John J Rossi
Journal:  Nat Rev Genet       Date:  2007-03       Impact factor: 53.242

3.  ON01910, a non-ATP-competitive small molecule inhibitor of Plk1, is a potent anticancer agent.

Authors:  Kiranmai Gumireddy; M V Ramana Reddy; Stephen C Cosenza; R Boominathan; R Boomi Nathan; Stacey J Baker; Nabisa Papathi; Jiandong Jiang; James Holland; E Premkumar Reddy
Journal:  Cancer Cell       Date:  2005-03       Impact factor: 31.743

4.  Prognostic significance of polo-like kinase (PLK) expression in squamous cell carcinomas of the head and neck.

Authors:  R Knecht; R Elez; M Oechler; C Solbach; C von Ilberg; K Strebhardt
Journal:  Cancer Res       Date:  1999-06-15       Impact factor: 12.701

5.  Polo-like kinase-1 is a target of the DNA damage checkpoint.

Authors:  V A Smits; R Klompmaker; L Arnaud; G Rijksen; E A Nigg; R H Medema
Journal:  Nat Cell Biol       Date:  2000-09       Impact factor: 28.824

6.  Long circulation of intravenously administered plasmid DNA delivered with dendritic poly(L-lysine) in the blood flow.

Authors:  Takahito Kawano; Tatsuya Okuda; Haruhiko Aoyagi; Takuro Niidome
Journal:  J Control Release       Date:  2004-09-30       Impact factor: 9.776

7.  Inhibition of influenza virus production in virus-infected mice by RNA interference.

Authors:  Qing Ge; Lily Filip; Ailin Bai; Tam Nguyen; Herman N Eisen; Jianzhu Chen
Journal:  Proc Natl Acad Sci U S A       Date:  2004-06-01       Impact factor: 11.205

8.  Enhancement of doxorubicin cytotoxicity on human esophageal squamous cell carcinoma cells by indomethacin and 4-[5-(4-chlorophenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide (SC236) via inhibiting P-glycoprotein activity.

Authors:  Le Yu; William Ka Kei Wu; Zhi Jie Li; Qi Cai Liu; Hai Tao Li; Ya Chun Wu; Chi Hin Cho
Journal:  Mol Pharmacol       Date:  2009-03-05       Impact factor: 4.436

9.  Evaluation of pH-dependent membrane-disruptive properties of poly(acrylic acid) derived polymers.

Authors:  Chirasak Kusonwiriyawong; Petra van de Wetering; Jeffrey A Hubbell; Hans P Merkle; Elke Walter
Journal:  Eur J Pharm Biopharm       Date:  2003-09       Impact factor: 5.571

10.  Biophysical and structural characterization of polyethylenimine-mediated siRNA delivery in vitro.

Authors:  Amy C Richards Grayson; Anne M Doody; David Putnam
Journal:  Pharm Res       Date:  2006-08       Impact factor: 4.580

View more
  26 in total

1.  Synthesis of folate-functionalized RAFT polymers for targeted siRNA delivery.

Authors:  Danielle S W Benoit; Selvi Srinivasan; Andrew D Shubin; Patrick S Stayton
Journal:  Biomacromolecules       Date:  2011-06-10       Impact factor: 6.988

2.  pH-activated nanoparticles for controlled topical delivery of farnesol to disrupt oral biofilm virulence.

Authors:  Benjamin Horev; Marlise I Klein; Geelsu Hwang; Yong Li; Dongyeop Kim; Hyun Koo; Danielle S W Benoit
Journal:  ACS Nano       Date:  2015-02-13       Impact factor: 15.881

Review 3.  Delivery of intracellular-acting biologics in pro-apoptotic therapies.

Authors:  Hongmei Li; Chris E Nelson; Brian C Evans; Craig L Duvall
Journal:  Curr Pharm Des       Date:  2011       Impact factor: 3.116

4.  Nanoparticle-mediated gene silencing confers radioprotection to salivary glands in vivo.

Authors:  Szilvia Arany; Danielle S W Benoit; Stephen Dewhurst; Catherine E Ovitt
Journal:  Mol Ther       Date:  2013-03-19       Impact factor: 11.454

5.  Controlling mesenchymal stem cell gene expression using polymer-mediated delivery of siRNA.

Authors:  Danielle S W Benoit; Molly E Boutin
Journal:  Biomacromolecules       Date:  2012-10-11       Impact factor: 6.988

6.  Anthracycline Nano-Delivery Systems to Overcome Multiple Drug Resistance: A Comprehensive Review.

Authors:  Ping Ma; Russell J Mumper
Journal:  Nano Today       Date:  2013-06-01       Impact factor: 20.722

7.  Influence of nano-carrier architecture on in vitro siRNA delivery performance and in vivo biodistribution: polyplexes vs micelleplexes.

Authors:  Dana J Gary; Hoyoung Lee; Rahul Sharma; Jae-Sung Lee; Youngwook Kim; Zheng Yun Cui; Di Jia; Valorie D Bowman; Paul R Chipman; Lei Wan; Yi Zou; Guangzhao Mao; Keunchil Park; Brittney-Shea Herbert; Stephen F Konieczny; You-Yeon Won
Journal:  ACS Nano       Date:  2011-04-06       Impact factor: 15.881

8.  Retroductal Nanoparticle Injection to the Murine Submandibular Gland.

Authors:  Jomy J Varghese; Isaac L Schmale; Yuchen Wang; Mollie Eva Hansen; Shawn D Newlands; Catherine E Ovitt; Danielle S W Benoit
Journal:  J Vis Exp       Date:  2018-05-03       Impact factor: 1.355

9.  Expression of αB-crystallin overrides the anti-apoptotic activity of XIAP.

Authors:  Jee Suk Lee; Hye Young Kim; Na Young Jeong; Sang Yeob Lee; Young Geol Yoon; Yung Hyun Choi; Chunlan Yan; In-Sun Chu; Hyungjong Koh; Hwan Tae Park; Young Hyun Yoo
Journal:  Neuro Oncol       Date:  2012-10-16       Impact factor: 12.300

10.  Macrophage-specific RNA interference targeting via "click", mannosylated polymeric micelles.

Authors:  Shann S Yu; Cheryl M Lau; Whitney J Barham; Halina M Onishko; Christopher E Nelson; Hongmei Li; Chelsey A Smith; Fiona E Yull; Craig L Duvall; Todd D Giorgio
Journal:  Mol Pharm       Date:  2013-02-12       Impact factor: 4.939

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.